Breaking News From Pharma & Bio Ingredients
Wyeth Releases 4th Quarter Earnings
Posted on 2006-01-31 13:33:00
Wyeth reported results for the 2005 fourth quarter and full year. Worldwide net revenue increased 2% to $4.7 billion for the 2005 fourth quarter and 8% to $18.8 billion for the 2005 full year. Excluding the negative impact of foreign exchange, worldwide net revenue increased 5% for the 2005 fourth quarter. There was no foreign exchange impact for the 2005 full year.
“Wyeth demonstrated strong product performance and 2005 was a year of significant strategic accomplishment," said Robert Essner, chairman, president and chief executive officer. "With strong growth from biotechnology products such as Enbrel and our vaccine, Prevnar, and contributions from our core pharmaceutical products such as Effexor and Protonix, Wyeth is in the strongest competitive position in its history with five product franchises exceeding one billion dollars in annual revenues."
Subscribe via RSS
